While we eagerly await the results of ongoing trials (DAPA ACT HF-TIMI 68,DICTATE-AHF, EMPACT-MI), we recommend starting SGLT2 inhibitors during an AHFadmission as soon as an adequate initial response to diuretic, vasodilator and/orinotropic treatment has been checked and the patient can tolerate oral food. The gene discussed is SLC5A2; the disease is hydrops fetalis.